sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_0050782> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_0050782> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB01129> ;
    a rdf:Statement ;
    rdfs:label "rabeprazole sodium delayed release tablets is a proton pump inhibitor ppi indicated in adults for healing of erosive or ulcerative gastroesophageal reflux disease gerd 1 1 maintenance of healing of erosive or ulcerative gerd 1 2 treatment of symptomatic gerd 1 3 healing of duodenal ulcers 1 4 helicobacter pylori 1 5 treatment of pathological hypersecretory conditions including zollinger ellison syndrome 1 6 in adolescent patients 12 years of age and older for short term treatment of symptomatic gerd 1 7 rabeprazole sodium delayed release tablets is indicated for short term 4 to 8 weeks treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease gerd for those patients who have not healed after 8 weeks of treatment an additional 8 week course of rabeprazole sodium delayed release tablets may be considered rabeprazole sodium delayed release tablets is indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease gerd maintenance controlled studies do not extend beyond 12 months rabeprazole sodium delayed release tablets is indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with gerd in adults for up to 4 weeks rabeprazole sodium delayed release tablets is indicated for short term up to four weeks treatment in the healing and symptomatic relief of duodenal ulcers most patients heal within four weeks rabeprazole sodium delayed release tablets in combination with amoxicillin and clarithromycin as a three drug regimen is indicated for the treatment of patients with h pylori h pylori h pylori see clinical studies 14 5 dosage and administration 2 5 in patients who fail therapy susceptibility testing should be done if resistance to clarithromycin is demonstrated or susceptibility testing is not possible alternative antimicrobial therapy should be instituted see clinical pharmacology 12 2 clinical pharmacology 12 2 rabeprazole sodium delayed release tablets is indicated for the long term treatment of pathological hypersecretory conditions including zollinger ellison syndrome rabeprazole sodium delayed release tablets is indicated for the treatment of symptomatic gerd in adolescents 12 years of age and above for up to 8 weeks" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB01129> bl:category bl:Drug .
}